Greater Cannabis Company, Inc., a firm focused on the development and commercialization of cannabinoid therapeutics, has released its Form 10-Q report for the third quarter of 2025. The report provides a detailed overview of the company’s financial performance and operational activities, highlighting significant challenges and strategic shifts in its business model.
Financial Highlights
- Total Revenue: $0, The Company had no revenue during each of the nine months ended September 30, 2025, and 2024.
- Income (Loss) from Operations: $(129,199), Operating expenses increased to $129,199 for the nine months ended September 30, 2025, from $118,651 for the same period of 2024.
- Net Loss: $(669,369), The net loss for the nine months ended September 30, 2025, was significantly higher compared to the net loss of $135,693 during the same period in 2024.
- Basic and Diluted Income (Loss) Per Common Share: $(.85), The loss per share increased from $(.25) in the same period of 2024.
Business Highlights
- Business Model Shift: The Greater Cannabis Company, Inc. shifted its business model in 2018 to focus on the development and commercialization of cannabinoid therapeutics, moving away from e-commerce and direct investment operations.
- License Agreement with Shaare Zedek Scientific Ltd.: In October 2021, the company entered into a license agreement with Shaare Zedek Scientific Ltd. to develop a novel cannabinoid therapeutic for neuropsychiatric disorders, including autism and schizophrenia.
- Research and Development Focus: The company is collaborating with Dr. Adi Aran, a renowned expert in cannabis research, to conduct clinical studies on a new combination therapy believed to be more effective than previous cannabis-only formulations.
- Clinical Trials and Investment: The company plans to invest up to $1,000,000 in clinical studies for the cannabinoid-based therapeutic, with an expected timeline of up to two years to complete these studies.
- Operational Challenges: The company has faced challenges in generating revenue from its initial product, an oral transmucosal patch platform, leading to a strategic pivot towards new therapeutic opportunities.
- Future Outlook: The company aims to conduct clinical studies and commercialize its cannabinoid-based therapeutic while exploring cannabis-related investment and development opportunities through various strategic partnerships.
SEC Filing: Greater Cannabis Company, Inc. [ GCAN ] – 10-Q – Nov. 12, 2025
